These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30328412)

  • 1. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
    Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
    Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
    Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
    J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
    Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
    Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
    Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
    Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
    Heringlake S; Hofdmann M; Fiebeler A; Manns MP; Schmiegel W; Tannapfel A
    J Hepatol; 2010 Feb; 52(2):220-7. PubMed ID: 20036025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
    Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
    Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
    Han C; Gao L; Bai H; Dou X
    Oncol Lett; 2018 Dec; 16(6):7123-7130. PubMed ID: 30546447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Wu CY; Jan YJ; Ko BS; Wu YJ; Wu YJ; Liou JY
    Anticancer Res; 2018 Dec; 38(12):6855-6863. PubMed ID: 30504401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
    Tsuzura H; Genda T; Sato S; Murata A; Kanemitsu Y; Narita Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Ichida T
    Int J Mol Sci; 2014 Apr; 15(4):6556-68. PubMed ID: 24747592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.
    Wang Z; Pei Y; Li W; Zhang J; Liu J
    PLoS One; 2022; 17(12):e0279591. PubMed ID: 36584078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
    Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
    World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
    Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
    Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
    Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
    Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
    Liu TA; Jan YJ; Ko BS; Wu YJ; Lu YJ; Liang SM; Liu CC; Chen SC; Wang J; Shyue SK; Liou JY
    Oncotarget; 2015 Nov; 6(36):38967-82. PubMed ID: 26516929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
    Xie C; Ye X; Zeng L; Zeng X; Cao D
    J Gastroenterol; 2023 Oct; 58(10):1030-1042. PubMed ID: 37500927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
    Orita N; Kawaguchi K; Honda M; Shimode T; Hayakawa N; Terashima T; Komura T; Nishikawa M; Horii R; Nio K; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S; Kagaya T; Yamashita T
    Biochem Biophys Res Commun; 2023 Sep; 674():133-139. PubMed ID: 37419034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
    Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
    World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.